Fig. 1
From: Metastatic colorectal cancer responsive to regorafenib for 2 years: a case report
Summary of the treatments. Trends of carcinoembryonic antigen levels is shown by solid lines. Low level of the tumor markers has been maintained throughout the treatment with regorafenib. CEA Carcinoembryonic antigen, FOLFIRI Folinic acid, fluorouracil, and irinotecan therapy, XELOX Capecitabine and oxaliplatin, Bv Bevacizumab, c-mab Cetuximab, LV Leucovorin, FU Fluorouracil, p-mab Panitumumab, IRIS ​irinotecan and S-1, UFT tegafur and uracil